skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.08d (Release date: 2017-08-28)
SearchBox Top
SearchBox Bottom
XL820 (Code C49090)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: XL820

Definition: An orally bioavailable, small molecule receptor tyrosine kinase inhibitor with potential antineoplastic activity. XL820 binds to and inhibits the receptor tyrosine kinases for vascular endothelial growth factor (VEGF), c-kit, and platelet-derived growth factor (PDGF). In tumor models of breast carcinomas, gliomas, and leukemia, this agent exhibits dose-dependent growth inhibition and has been shown to cause tumor regression.

Label: XL820

NCI Thesaurus Code: C49090 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C1710687  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)

External Source Codes: 
PDQ Closed Trial Search ID 452042
PDQ Open Trial Search ID 452042 (check for NCI PDQ open clinical trial info)
UMLS CUI C1710687

Other Properties:
     Name Value (qualifiers indented underneath)
code C49090
Legacy_Concept_Name XL820
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom